{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:26:04Z","timestamp":1793316364008,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:00:00Z","timestamp":1759536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:00:00Z","timestamp":1759536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"BeOne Medicines, Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Several programmed cell death protein-1 inhibitors are approved for the first-line treatment of advanced gastric\/gastroesophageal junction cancer, including pembrolizumab, nivolumab and, more recently, tislelizumab. Since direct comparisons between these agents are lacking, advanced statistical modeling can be utilized to evaluate the relative efficacy and safety of tislelizumab compared with other first-line immunotherapy regimens in this indication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic literature review was performed to identify and summarize published randomized controlled trials investigating first-line treatments in adult patients with unresectable, locally advanced, or metastatic human epidermal growth factor receptor 2-negative gastric\/gastroesophageal junction cancer. Relevant trials were synthesized using a Bayesian network meta-analysis; fixed-effect models were conducted for all analyses. The network meta-analysis base case used the intent-to-treat populations for tislelizumab\u2009+\u2009chemotherapy and placebo\u2009+\u2009chemotherapy from RATIONALE-305.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Key comparators included nivolumab\u2009+\u2009chemotherapy (ATTRACTION-4, CheckMate 649), and pembrolizumab\u2009+\u2009chemotherapy (KEYNOTE-062, KEYNOTE-859). Tislelizumab\u2009+\u2009chemotherapy demonstrated similar efficacy compared with nivolumab\u2009+\u2009chemotherapy and pembrolizumab\u2009+\u2009chemotherapy for both overall survival and progression-free survival. Tislelizumab\u2009+\u2009chemotherapy was associated with significantly lower odds of grade\u2009\u2265\u20093 treatment-related adverse events compared with nivolumab\u2009+\u2009chemotherapy, and there were no statistically significant differences between tislelizumab\u2009+\u2009chemotherapy compared with pembrolizumab\u2009+\u2009chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Overall, these analyses suggest that tislelizumab\u2009+\u2009chemotherapy is similarly efficacious to pembrolizumab\u2009+\u2009chemotherapy and nivolumab\u2009+\u2009chemotherapy, and is associated with a similar or lower incidence of grade\u2009\u2265\u20093 treatment-related adverse events in the first-line treatment of gastric\/gastroesophageal junction cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10120-025-01660-4","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T12:55:44Z","timestamp":1759582544000},"page":"1021-1032","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comparative efficacy and safety of tislelizumab and other programmed cell death protein 1 inhibitors in first-line treatment of advanced gastroesophageal cancers: a systematic review and network meta-analysis"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9946-0629","authenticated-orcid":false,"given":"Jaffer A.","family":"Ajani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Alsina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Moehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keun-Wook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Steenkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Prentiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaijun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Becky","family":"Hooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,4]]},"reference":[{"key":"1660_CR1","doi-asserted-by":"publisher","first-page":"101404","DOI":"10.1016\/j.eclinm.2022.101404","volume":"47","author":"E Morgan","year":"2022","unstructured":"Morgan E, Arnold M, Camargo MC, Gini A, Kunzmann AT, Matsuda T, et al. The current and future incidence and mortality of gastric cancer in 185 countries, 2020\u201340: a population-based modelling study. EClinicalMedicine. 2022;47:101404.","journal-title":"EClinicalMedicine"},{"key":"1660_CR2","unstructured":"Menon G, El-Nakeep S, Babiker H. Gastric Cancer. StatPearls [Internet]: Treasure Island; 2025."},{"key":"1660_CR3","unstructured":"American Cancer Society. What Is Stomach Cancer? 2021. Available from: https:\/\/www.cancer.org\/cancer\/types\/stomach-cancer\/about\/what-is-stomach-cancer.html. Accessed 6 May 2025"},{"issue":"7517","key":"1660_CR4","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202\u20139.","journal-title":"Nature"},{"issue":"5","key":"1660_CR5","doi-asserted-by":"publisher","first-page":"169","DOI":"10.6004\/jnccn.2025.0022","volume":"23","author":"JA Ajani","year":"2025","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, Corvera CU, Das P, Enzinger PC, et al. Gastric cancer, version 2.2025 NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2025;23(5):169\u201391.","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"1660_CR6","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):1005\u201320.","journal-title":"Ann Oncol"},{"issue":"4","key":"1660_CR7","doi-asserted-by":"publisher","first-page":"393","DOI":"10.6004\/jnccn.2023.0019","volume":"21","author":"JA Ajani","year":"2023","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, Cooke D, Corvera C, Das P, et al. Esophageal and esophagogastric junction cancers, version 2.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023;21(4):393\u2013422.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"1660_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.semradonc.2012.09.008","volume":"23","author":"MF Buas","year":"2013","unstructured":"Buas MF, Vaughan TL. Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease. Semin Radiat Oncol. 2013;23(1):3\u20139.","journal-title":"Semin Radiat Oncol"},{"issue":"7","key":"1660_CR9","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1002\/jso.26844","volume":"125","author":"JY Xia","year":"2022","unstructured":"Xia JY, Aadam AA. Advances in screening and detection of gastric cancer. J Surg Oncol. 2022;125(7):1104\u20139.","journal-title":"J Surg Oncol"},{"issue":"10","key":"1660_CR10","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1016\/j.dld.2024.02.008","volume":"56","author":"F Farinati","year":"2024","unstructured":"Farinati F, Pelizzaro F. Gastric cancer screening in Western countries: a call to action. Dig Liver Dis. 2024;56(10):1653\u201362.","journal-title":"Dig Liver Dis"},{"issue":"4","key":"1660_CR11","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s10555-020-09925-3","volume":"39","author":"RE Sexton","year":"2020","unstructured":"Sexton RE, Al Hallak MN, Diab M, Azmi AS. Gastric cancer: a comprehensive review of current and future treatment strategies. Cancer Metastasis Rev. 2020;39(4):1179\u2013203.","journal-title":"Cancer Metastasis Rev"},{"issue":"17","key":"1660_CR12","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.3748\/wjg.v25.i17.2029","volume":"25","author":"L Necula","year":"2019","unstructured":"Necula L, Matei L, Dragu D, Neagu AI, Mambet C, Nedeianu S, et al. Recent advances in gastric cancer early diagnosis. World J Gastroenterol. 2019;25(17):2029\u201344.","journal-title":"World J Gastroenterol"},{"issue":"31","key":"1660_CR13","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","volume":"24","author":"E Van Cutsem","year":"2006","unstructured":"Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24(31):4991\u20137.","journal-title":"J Clin Oncol"},{"issue":"10251","key":"1660_CR14","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396(10251):635\u201348.","journal-title":"Lancet"},{"issue":"7","key":"1660_CR15","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.3390\/jcm12072636","volume":"12","author":"Y Narita","year":"2023","unstructured":"Narita Y, Muro K. Updated immunotherapy for gastric cancer. J Clin Med. 2023;12(7):2636.","journal-title":"J Clin Med"},{"key":"1660_CR16","unstructured":"KEYTRUDA\u00ae (pembrolizumab) [prescribing information]. Rahway, NJ Merck & Co. 06\/2025."},{"key":"1660_CR17","unstructured":"OPDIVO\u00ae (nivolumab) [prescribing information] Princeton, NJ: Bristol Myers Squibb. 05\/2025."},{"key":"1660_CR18","unstructured":"European Medicines Agency. Opdivo (nivolumab) Summary of Product Characteristics. 2025."},{"key":"1660_CR19","unstructured":"European Medicines Agency. Keytruda (pembrolizumab) Summary of Product Characteristics. 2025."},{"issue":"1","key":"1660_CR20","doi-asserted-by":"publisher","first-page":"153","DOI":"10.5230\/jgc.2025.25.e10","volume":"25","author":"SS Eom","year":"2025","unstructured":"Eom SS, Ryu KW, Han HS, Kong SH. A comprehensive and comparative review of global gastric cancer treatment guidelines: 2024 update. J Gastric Cancer. 2025;25(1):153\u201376.","journal-title":"J Gastric Cancer"},{"key":"1660_CR21","unstructured":"Lordick F, Candia Montero L, Castelo-Branco L, Pentheroudakis G, Sessa C, E. S. ESMO Gastric Cancer Living Guideline (version 1.4 Sep 2024) [Internet]. Lugano: European Society for Medical Oncology; 2024 []. Available from: https:\/\/www.esmo.org\/guidelines\/living-guidelines\/esmo-living-guideline-gastric-cancer\/metastatic-disease\/first-line-for-her2-negative. Accessed 12 June 2025."},{"key":"1660_CR22","unstructured":"TEVIMBRA\u00ae (tislelizumab-jsgr) [prescribing information]. Pennington, NJ, BeOne Medicines, Ltd. 04\/2025."},{"key":"1660_CR23","unstructured":"European Medicines Agency. Tevimbra (tislelizumab) Summary of Product Characteristics. 2025."},{"key":"1660_CR24","doi-asserted-by":"publisher","first-page":"e078876","DOI":"10.1136\/bmj-2023-078876","volume":"385","author":"MZ Qiu","year":"2024","unstructured":"Qiu MZ, Oh DY, Kato K, Arkenau T, Tabernero J, Correa MC, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. BMJ. 2024;385:e078876.","journal-title":"BMJ"},{"key":"1660_CR25","doi-asserted-by":"crossref","unstructured":"Moehler M, Oh DY, Kato K, Tabernero J, Cruz-Correa M, Wyrwicz L, et al. Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in HER2-negative advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma (GC\/GEJC): PD-L1 biomarker analysis from RATIONALE-305. Ann Oncol 2024;35:S160\u201361.","DOI":"10.1016\/j.annonc.2024.05.312"},{"key":"1660_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03133-7","author":"M Moehler","year":"2025","unstructured":"Moehler M, Oh D-Y, Kato K, Arkenau T, Tabernero J, Lee K-W, et al. First-line tislelizumab plus chemotherapy for advanced gastric cancer with programmed death-ligand 1 expression \u2265 1%: a retrospective analysis of RATIONALE-305. Adv Ther. 2025;42:2248\u201368.","journal-title":"Adv Ther"},{"key":"1660_CR27","unstructured":"Higgins JPT TJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane handbook for systematic reviews of interventions version 6.2 Chichester (UK): John Wiley & Sons; 2021 [updated February 20212024]. Available from: www.training.cochrane.org\/handbook."},{"key":"1660_CR28","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"1660_CR29","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jclinepi.2021.02.003","volume":"134","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement. J Clin Epidemiol. 2021;134:103\u201312.","journal-title":"J Clin Epidemiol"},{"key":"1660_CR30","unstructured":"Dias S, Welton NJ, Sutton AJ, Ades A. NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. 2014. Available from https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK310366\/. Accessed 26 Sept 2025."},{"issue":"2","key":"1660_CR31","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","volume":"64","author":"G Salanti","year":"2011","unstructured":"Salanti G, Ades A, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64(2):163\u201371.","journal-title":"J Clin Epidemiol"},{"key":"1660_CR32","doi-asserted-by":"publisher","first-page":"104216","DOI":"10.1016\/j.critrevonc.2023.104216","volume":"193","author":"T Cai","year":"2024","unstructured":"Cai T, Liang L, Zhao X, Lin C, Li D, Zheng J. Comparative efficacy and tolerability of first-line treatments for untreated, HER2-negative, advanced gastric cancer: systematic review and network meta-analysis. Crit Rev Oncol Hematol. 2024;193:104216.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1660_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32020112","author":"W Zhang","year":"2025","unstructured":"Zhang W, Guo K, Zheng S. Immunotherapy combined with chemotherapy in the first-line treatment of advanced gastric cancer: systematic review and Bayesian network meta-analysis based on specific PD-L1 CPS. Curr Oncol. 2025;32(2):112.","journal-title":"Curr Oncol"},{"issue":"6","key":"1660_CR34","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1097\/MS9.0000000000000765","volume":"85","author":"L Fan","year":"2023","unstructured":"Fan L, Lu N, Zhang L, Zhang J, Li J, Cui M, et al. First-line treatment options for advanced gastric\/gastroesophageal junction cancer patients with PD-L1-positive: a systematic review and meta-analysis. Ann Med Surg. 2023;85(6):2875\u201383.","journal-title":"Ann Med Surg"},{"issue":"4","key":"1660_CR35","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1159\/000531457","volume":"68","author":"S Fei","year":"2023","unstructured":"Fei S, Lu Y, Chen J, Qi J, Wu W, Wang B, et al. Efficacy of PD-1 inhibitors in first-line treatment for advanced gastroesophageal junction and gastric cancer by subgroups: a systematic review and meta-analysis. Chemotherapy. 2023;68(4):197\u2013209.","journal-title":"Chemotherapy"},{"issue":"7","key":"1660_CR36","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1177\/21925682221110527","volume":"12","author":"JR Dettori","year":"2022","unstructured":"Dettori JR, Norvell DC, Chapman JR. Fixed-effect vs random-effects models for meta-analysis: 3 points to consider. Glob Spine J. 2022;12(7):1624\u20136.","journal-title":"Glob Spine J"},{"issue":"22","key":"1660_CR37","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.2217\/fon-2023-0301","volume":"20","author":"A Haiderali","year":"2024","unstructured":"Haiderali A, Huang M, Pan W, Akers KG, Maciel D, Frederickson AM. Pembrolizumab plus chemotherapy for first-line treatment of advanced triple-negative breast cancer. Future Oncol. 2024;20(22):1587\u2013600.","journal-title":"Future Oncol"},{"issue":"10","key":"1660_CR38","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","volume":"6","author":"K Shitara","year":"2020","unstructured":"Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol. 2020;6(10):1571\u201380.","journal-title":"JAMA Oncol"},{"issue":"7903","key":"1660_CR39","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/s41586-022-04508-4","volume":"603","author":"K Shitara","year":"2022","unstructured":"Shitara K, Ajani JA, Moehler M, Garrido M, Gallardo C, Shen L, et al. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature. 2022;603(7903):942\u20138.","journal-title":"Nature"},{"issue":"11","key":"1660_CR40","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh DY, Yanez P, Bai Y, Ryu MH, Lee J, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(11):1181\u201395.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1660_CR41","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"YK Kang","year":"2022","unstructured":"Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(2):234\u201347.","journal-title":"Lancet Oncol"},{"key":"1660_CR42","unstructured":"U.S. Food and Drug Administration. FDA Briefing Document: Immune checkpoint inhibitors in patients with metastatic or unresectable HER2-negative gastric adenocarcinoma. Oncology Advisory Committee Meeting September 26, 2024. Available at: https:\/\/www.fdagov\/media\/182138\/download. Accessed 6 May 2025."},{"key":"1660_CR43","doi-asserted-by":"publisher","first-page":"e2400230","DOI":"10.1200\/PO.24.00230","volume":"8","author":"SJ Klempner","year":"2024","unstructured":"Klempner SJ, Cowden ES, Cytryn SL, Fassan M, Kawakami H, Shimada H, et al. PD-L1 Immunohistochemistry in gastric cancer: comparison of combined positive score and tumor area positivity across 28\u20138, 22C3, and SP263 assays. JCO Precis Oncol. 2024;8:e2400230.","journal-title":"JCO Precis Oncol"},{"key":"1660_CR44","unstructured":"BeiGene. Clinical Study Report: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) plus Platinum and Fluoropyrimidine Versus Placebo plus Platinum and Fluoropyrimidine as First Line Treatment in Patients with Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. 2023."},{"issue":"1","key":"1660_CR45","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1159\/000519602","volume":"103","author":"N Manabe","year":"2022","unstructured":"Manabe N, Matsueda K, Haruma K. Epidemiological review of gastroesophageal junction adenocarcinoma in Asian countries. Digestion. 2022;103(1):29\u201336.","journal-title":"Digestion"},{"key":"1660_CR46","doi-asserted-by":"publisher","first-page":"107327482211112","DOI":"10.1177\/10732748221111296","volume":"29","author":"L Zhang","year":"2022","unstructured":"Zhang L, Geng Z, Hao B, Geng Q. Tislelizumab: a modified anti-tumor programmed death receptor 1 antibody. Cancer Control. 2022;29:10732748221111296.","journal-title":"Cancer Control"},{"issue":"7","key":"1660_CR47","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00262-018-2160-x","volume":"67","author":"T Zhang","year":"2018","unstructured":"Zhang T, Song X, Xu L, Ma J, Zhang Y, Gong W, et al. The binding of an anti-PD-1 antibody to FcgammaRIota has a profound impact on its biological functions. Cancer Immunol Immunother. 2018;67(7):1079\u201390.","journal-title":"Cancer Immunol Immunother"},{"key":"1660_CR48","doi-asserted-by":"publisher","first-page":"1328193","DOI":"10.3389\/fimmu.2024.1328193","volume":"15","author":"O Goldmann","year":"2024","unstructured":"Goldmann O, Nwofor OV, Chen Q, Medina E. Mechanisms underlying immunosuppression by regulatory cells. Front Immunol. 2024;15:1328193.","journal-title":"Front Immunol"},{"issue":"1","key":"1660_CR49","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-022-01282-8","volume":"15","author":"Y Tie","year":"2022","unstructured":"Tie Y, Tang F, Wei YQ, Wei XW. Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets. J Hematol Oncol. 2022;15(1):61.","journal-title":"J Hematol Oncol"},{"key":"1660_CR50","doi-asserted-by":"publisher","first-page":"108111","DOI":"10.1016\/j.pharmthera.2022.108111","volume":"236","author":"DR Principe","year":"2022","unstructured":"Principe DR, Kamath SD, Korc M, Munshi HG. The immune modifying effects of chemotherapy and advances in chemo-immunotherapy. Pharmacol Ther. 2022;236:108111.","journal-title":"Pharmacol Ther"},{"issue":"10294","key":"1660_CR51","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27\u201340.","journal-title":"Lancet"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-025-01660-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-025-01660-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-025-01660-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T14:29:01Z","timestamp":1763562541000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10120-025-01660-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,4]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1660"],"URL":"https:\/\/doi.org\/10.1007\/s10120-025-01660-4","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,4]]},"assertion":[{"value":"18 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article was originally published under the subscription model but it is now published under an Open Access license.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare financial and non-financial relationships with the following organizations that could have appeared to influence the work reported in this paper. WT, KW, and LZ are employees of BeOne Medicines. WT and LZ report stock or stock options from BeOne Medicines. JS, EP, and BH are employees of EVERSANA who received funding from BeOne Medicines for conducting the statistical analyses that informed this study. JA has received research grants or contracts from AstraZeneca, Bristol Myers Squibb, DeltaFly, Gilead, Jazz Pharmaceuticals, Merck Sharp & Dohme, Prolinx, Servier, Taiho Pharmaceuticals, and Zymeworks. JA reports consulting fees from Aadi, AstraZeneca, BeOne Medicines, Bristol Myers Squibb, Daiichi, Gilead, Jazz Pharmaceuticals, Kyowa-Kirin, Leap Therapeutics, Merck Sharpe and Dohme, Novartis, Servier, Taiho Pharmaceuticals, and Zymeworks; support for attending meetings and\/or travel from Astellas Pharma and Zymeworks; and\u00a0participation on a data safety monitoring board or advisory board from BeOne Medicines. MA reports consulting fees from Amgen, AstraZeneca, Bristol Myers Squibb, Lilly, Merck Sharp & Dohme, and Servier; and payment or honoraria received as a speaker and\/or in an advisory role from Amgen, AstraZeneca, Bristol Myers Squibb, Lilly, Merck Sharp & Dohme, Roche, and Servier; and support for attending meetings and\/or travel from\u00a0Lilly. MM reports consulting fees from Amgen, Astellas Pharma, AstraZeneca, Bayer, BeOne Medicines, Bristol Myers Squibb, Dragonfly, Lilly, Merck Serono, Merck Sharp & Dohme, Novartis, Pfizer, Roche\/Genentech, Servier, and Taiho Pharmaceuticals; payment or honoraria received as a speaker and\/or in an advisory role from Amgen, Astellas Pharma, AstraZeneca\/MedImmune, Bristol Myers Squibb, Daiichi Sankyo, Pierre Fabre, Falk Foundation, Merck Serono, Merck Sharp & Dohme, Nordic, Sanofi, Roche\/Genentech, Servier, and Transcenta; other financial or non-financial interests from Amgen, Bayer, BeOne Medicines, American Society of Clinical Oncology, German Cancer Society, European Organization for Research and Treatment of Cancer, European Society of Medical Oncology, Merck Serono, Merck Sharp & Dohme, and Roche\/Genentech. KL has received research grants or contracts from ALX Oncology, Amgen, Arcus Pharmaceuticals, Astellas Pharma, AstraZeneca\/MedImmune, BeOne Medicines, Bolt Biotherapeutics, Daiichi Sankyo, Elevar Therapeutics, Erasca, Exelixis, Genome & Company, GlaxoSmithKline, Hanmi, IgM Biosciences, Ildong Pharmaceuticals, InventBio, Jazz Pharmaceuticals, Leap Therapeutics, Macrogenics, Medicenna, MedPacto, Merck KGaA, Metafines, Merck Sharp & Dohme, Ono Pharmaceutical, Panolos Bioscience, Roche\/Genentech, Seagen, Taiho Pharmaceuticals, Trisula Therapeutics, Wellmarker Bio, and Y-BIOLOGICS; consulting fees from AbbVie, Astellas Pharma, Daiichi Sankyo, Metafines, and Merck Sharp & Dohme; and payment or honoraria received as a speaker and\/or in an advisory role from Astellas Pharma, Daiichi Sankyo, Merck KGaA, and Sanofi Aventis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}